Hinge Health, Inc. SEC Filings

Hinge Health, Inc. (HNGE) had a Form 4 filed for reporting person Robinson Elliott in connection with sales of its Class A Common Stock by affiliated investment funds. On August 19, 2026, Bessemer Venture Partners X L.P. sold 13,527 shares and Bessemer Venture Partners X Institutional L.P. sold 12,699 shares at a weighted average price of $90.05 per share in multiple transactions between $90.00 and $90.44. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the Bessemer Funds and expressly disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

Hinge Health, Inc. (HNGE) entered into a long-term office lease with 50 Beale Street LLC for approximately 119,278 rentable square feet at 300 Mission Street, San Francisco. The lease is expected to commence five business days after the August 18, 2026 execution date and is anticipated to expire on February 28, 2037.

Over the lease term, aggregate estimated base rent payments total approximately $86.0 million, with Hinge Health also responsible for its share of operating expenses, taxes, insurance, and other costs. The landlord will provide a $17.9 million tenant improvement allowance, and Hinge Health must post an $2.8 million irrevocable standby letter of credit. The lease includes one five-year renewal option and a one-time early termination right effective January 31, 2035, subject to conditions, including payment of a termination amount. The lease creates a direct financial obligation for the company.

Hinge Health, Inc. (HNGE) had a notice filed for a planned sale of common stock under Rule 144 by director Kristina Murphy Leslie. The notice covers 1,200 shares of common stock, held as restricted stock acquired on 04/01/2025, to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate value of $105,876.00 and a proposed sale date of 08/20/2026 on the NYSE.

Hinge Health, Inc. (HNGE) is the issuer for a planned resale of its Class A common stock under Rule 144. Bessemer Venture Partners X Institutional has filed to potentially sell up to 121,050 shares through Merrill Lynch on the NYSE, with an approximate sale date of 08/19/2026. The securities were originally acquired on 02/04/2020 in a cash private placement from the issuer. The filing lists 62,468,721 shares of this class as outstanding.

Hinge Health, Inc. (HNGE) received a Rule 144 notice that Bessemer Venture Partners X intends to sell up to 128,950 Class A shares through Merrill Lynch. The shares were acquired in a private placement from Hinge Health on 02/04/2020 for cash. Hinge Health had 62,468,721 Class A shares outstanding as of the notice, and the planned sale has an indicated aggregate market value of $11,130,964.

Hinge Health, Inc. received an amended Schedule 13G/A from several Insight Partners-affiliated funds and entities reporting their beneficial ownership of its equity. The Insight entities collectively beneficially own 6,441,830 shares of Class B Common Stock, each share exchangeable into one share of Class A Common Stock, and are treated as holding that same number of Class A shares for this calculation. Based on 62,468,721 Class A shares outstanding as of July 29, 2026 plus these as-converted Class B shares, the holding represents approximately 9.4% of the Class A Common Stock. The filing notes that if all outstanding Class B shares reported in the Form 10-Q were deemed converted, the Insight entities would beneficially own about 8.0% of the Class A shares deemed outstanding. Voting and dispositive power over these securities is reported as shared among the Insight funds and their general partners, which are making a single joint filing while expressly disclaiming being a “group” for other purposes.

Hinge Health, Inc. received an amended Schedule 13G reporting updated beneficial ownership in its Class A Common Stock, par value $0.00001 per share. The filing covers shares underlying Class B Common Stock that are convertible into Class A on a 1‑for‑1 basis. Deer X Ltd and Deer X LP each report beneficial ownership of 1,908,707 shares, representing 3.0% of the Class A Common Stock. Bessemer Venture Partners X L.P. reports 984,511 shares or 1.6%, and Bessemer Venture Partners X Institutional L.P. reports 924,196 shares or 1.5%. All reporting persons state sole voting and dispositive power over their respective holdings. The percentages are based on 62,468,721 Class A shares outstanding as of July 29, 2026, as disclosed in the issuer’s Form 10‑Q.

Hinge Health, Inc. received an updated ownership report from investment entities affiliated with 11.2 Capital and Qian Zhuang regarding holdings of Class A common stock. As of June 30, 2026, the reporting group beneficially owned a total of 2,464,657 shares of Class A common stock, representing 4.0% of the outstanding class, based on 60,859,919 shares outstanding. These holdings consist of 1,911,977 shares held directly by 11.2 Capital I, L.P. and 552,680 shares held directly by 11.2 Capital IVY, LLC. Zhuang, as sole managing member of the relevant general partner and manager entities, has sole voting and dispositive power over the shares held by 11.2 Capital I, 11.2 Capital HH, and 11.2 Capital IVY. The reporting persons state that they own 5 percent or less of this class of securities.

Hinge Health, Inc. director Teddie Benjamin Wardi reported an indirect acquisition of 4,637 shares of Class A Common Stock. The shares were received by Ingentorsk (Delaware) LLC through distributions from Insight Venture Associates X, L.P. and Insight Venture Partners X (Class A), L.P., with no consideration paid. Wardi controls Ingentorsk and may be deemed the beneficial owner of these securities under Rule 16a-1.